Skip to content

Remimazolam in the Extraction of Impacted Wisdom Teeth

A Randomized Controlled Clinical Trial of Remimazolam Benzenesulfonate Usage in the Extraction of Impacted Wisdom Teeth

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05350085
Enrollment
150
Registered
2022-04-27
Start date
2022-04-18
Completion date
2023-10-01
Last updated
2023-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterograde Amnesia, Dental Anxiety, Sedation Complication

Brief summary

Benzodiazepines, represented by midazolam, are often used for sedation in outpatient surgery in dentistry. However, midazolam has the problems of slow consciousness recovery and long recovery time, which brings trouble to the patients. Remimazolam is a new type of ultra short acting sedative anesthetic. Compared with other similar products, remimazolam has faster effect, rapid metabolism and has no accumulation, which may mean that compared with midazolam, remimazolam has a better clinical application prospect in dental outpatient surgery.

Detailed description

The patients were randomly divided into midazolam group and remimazolam group. The onset time of drugs, postoperative recovery time, vital signs, anterograde amnesia and other complications were observed.

Interventions

DRUGRemimazolam besylate

① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 \ 8 minutes until Ramsay Sedation grade III,then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 \ 10mg/h,adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.

DRUGMidazolam

① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 \ 8 minutes until Ramsay Sedation grade III,then start dental operation; ② Maintenance dose: maintain the pump speed at 3 \ 6mg/h,adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.

Sponsors

Beijing Anzhen Hospital
CollaboratorOTHER
Beijing Shijitan Hospital, Capital Medical University
CollaboratorOTHER
Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

Consenting patients will be eligible if they: 1. Have mandibular impacted wisdom teeth that need to be extracted; 2. Have a body mass index (BMI) between 18.5 and 30 kg/m2; 3. Are aged between 18 and 60 years; 4. Have American Society of Anesthesiology (ASA) classification grade of I-II; 5. Have Modified Dental Anxiety Scale (MDAS) score \> 15; and 6. Volunteered to accept intravenous sedation.

Exclusion criteria

Patients will be ineligible if they: 1. Are pregnant; 2. Experience respiratory infections, asthma attack or persistent state; 3. Have contraindications to anaesthesia or a previous abnormal surgical anaesthesia recovery history; 4. Have severe cardiopulmonary insufficiency; 5. Have preoperative blood pressure \> 160/100 mmHg or diastolic blood pressure \> 100 mmHg, or blood pressure \< 90/60 mmHg; 6. Have a neuromuscular or mental disorder that renders them unable to communicate or cooperate effectively or sign informed consent; 7. Are suspected of abusing narcotic analgesics or sedatives; 8. Have a known allergy or contraindication to benzodiazepines; or 9. Have participated in other drug trials within 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Recovery time of complete alertnessDuring treatment in hospital, an expected average of 2 hoursCalculated from the cessation of sedative injection with micro injection pump, the patients were scored with the modified observer's assessment of alertness/sedation scale (MOAA/S) every 1 minute, and the first minute with MOAA/S score = 5 for 3 consecutive times. MOAA/S score: Range from 5(Awake) to 1(Unresponsive).

Secondary

MeasureTime frameDescription
Anterograde amnesia durationDuring treatment in hospital, an expected average of 2 hoursPatients were given 3 different cards(including animals, fruits, vegetables, vehicles)at 0, 15,30,60 minutes after complete alertness(described at primary outcome). They were asked to recall them immediately and delayed(approximately 5 minutes after Immediate memory).
Interruption reasons during operationDuring treatment in hospital, an expected average of 2 hoursIt includes chokes, hypoxia, continuous movement that makes treatment difficult, or other situations requiring suspension of operation.

Countries

China

Contacts

Primary ContactLijian Pei, MD
hazelbeijing@vip.163.com18612672127

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026